Clinical trial
A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.
NCT02971839 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2016
- Completion date
- August 31, 2017
- Enrollment
- 11 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.